Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.

Hum Vaccin Immunother · 2023 · PMC10438852 · PMID 37587615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

19 These results indicated the safety of two doses of the investigational vaccine in participants 3–8 years old, and the incidence of adverse reactions did not show an increasing trend with the number of doses.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.